ArticleInternational journal of immunopathology and pharmacology
Presepsin: A potential biomarker of PJI? A comparative analysis with known and new infection biomarkers.
Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- Bone and Infections: An Osteoimmunological Interplay.International journal of molecular sciences · 2026Review
- Serum Presepsin Might Not Detect Periprosthetic Joint Infection After Hip Arthroplasty.Journal of clinical medicine · 2025Article
- The Evaluation of New-Generation Biomarker sCD14ST Provides New Insight into COVID-19's Effect on Bone Remodeling.Journal of clinical medicine · 2025Article
- Analysis of Serum and Synovial Inflammatory Markers in Periprosthetic Joint Infections: A Narrative Review.Cureus · 2024Review
- Presepsin in Critical Illness: Current Knowledge and Future Perspectives.Diagnostics (Basel, Switzerland) · 2024Review
- Current Status and Perspectives of Diagnosis and Treatment of Periprosthetic Joint Infection.Infection and drug resistance · 2024Review
- Physiologic postoperative presepsin kinetics following primary cementless total hip arthroplasty: A prospective observational study.World journal of orthopedics · 2023Article
- Joint fluid interleukin-6 combined with the neutral polymorphonuclear leukocyte ratio (PMN%) as a diagnostic index for chronic periprosthesis infection after arthroplasty.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2023Article
- Diagnosis of Periprosthetic Joint Infection: The Utility of Biomarkers in 2023.Antibiotics (Basel, Switzerland) · 2023Review
- Presepsin as a diagnostic biomarker of peri-prosthetic joint infection: a review of the literature.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2023Review
- The Challenge of Periprosthetic Joint Infection Diagnosis: From Current Methods to Emerging Biomarkers.International journal of molecular sciences · 2023Review
- Profiling the Immune Response to Periprosthetic Joint Infection and Non-Infectious Arthroplasty Failure.Antibiotics (Basel, Switzerland) · 2023Review
- What's New in the Diagnosis of Periprosthetic Joint Infections: Focus on Synovial Fluid Biomarkers.Tropical medicine and infectious disease · 2022Review
- The Usefulness of Synovial Fluid Proteome Analysis in Orthopaedics: Focus on Osteoarthritis and Periprosthetic Joint Infections.Journal of functional morphology and kinesiology · 2022Review
- Dynamic blood presepsin levels are associated with severity and outcome of acute pancreatitis: A prospective cohort study.World journal of gastroenterology · 2022Article
- SCD14-ST and New Generation Inflammatory Biomarkers in the Prediction of COVID-19 Outcome.Biomolecules · 2022Article
- Globulin, the albumin-to-globulin ratio, and fibrinogen perform well in the diagnosis of Periprosthetic joint infection.BMC musculoskeletal disorders · 2021Article
- The Expanding Role of Biomarkers in Diagnosing Infection in Total Joint Arthroplasty: A Review of Current Literature.The archives of bone and joint surgery · 2021Review
- Current Clinical Methods for Detection of Peri-Prosthetic Joint Infection.Surgical infections · 2020Review
- Improved diagnosis of chronic hip and knee prosthetic joint infection using combined serum and synovial IL-6 tests.Bone & joint research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is still no "gold standard" for the diagnosis and prognosis of post-operative periprosthetic joint infection (PJI). Among serum biomarkers, an emerging molecule is presepsin, the soluble fraction of CD14, recently described in other settings as a powerful diagnostic tool to detect sepsis at different degrees of severity. The aim of this study was to investigate the diagnostic and prognostic value of presepsin in PJI. A total of 30 patients with PJI and 30 patients without PJI were enrolled. Presepsin, C-reactive protein (CRP), serum interleukin (IL)-6, triggering receptor expressed on myeloid cells 1 (TREM-1), CCL2, matrix metalloproteinase 9 (MMP-9), CD163, osteopontin (OPN), and toll-like receptor 2 (TLR2) were measured at different times after surgery. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were analyzed for each biomarker. Presepsin showed greater diagnostic value than CRP and IL-6; CD163, TREM-1, and MMP-9 had very low diagnostic potential. Presepsin, OPN, CCL2, suPAR, and TLR2 all decreased significantly with increasing time of recovery after surgery in PJI patients. Presepsin can be considered a useful tool for the diagnosis and clinical monitoring of PJI and can be backed by a panel of new inflammatory markers involved in monocyte-/macrophage-mediated inflammatory responses, such as OPN, CCL2, TLR2, and suPAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.